ABT 354

Drug Profile

ABT 354

Alternative Names: ABT354

Latest Information Update: 23 Dec 2013

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 01 Nov 2013 AbbVie completes a phase I trial study in Alzheimer's disease in USA (NCT01908010)
  • 01 Jul 2013 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)
  • 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top